Vatica Health (Frazier) Merges with Cozeva

Frazier Healthcare Partners Acquires Vatica Health

September 25, 2023

Healthcare Services

Frazier Healthcare Partners has acquired Vatica Health, a provider‑centric risk adjustment and value‑based care services company headquartered in Alpharetta, Georgia. TripleTree served as financial advisor to Vatica; terms were not disclosed. The deal expands Frazier’s exposure to risk adjustment, clinical documentation and value‑based care capabilities.

Hims & Hers Acquires ZAVA

June 3, 2025

Healthcare Services

Hims & Hers Health, Inc. agreed to acquire ZAVA, a leading European digital health and telemedicine platform, in an all-cash transaction to accelerate the company's expansion into the UK and launch operations in Germany, France and Ireland. The acquisition brings ZAVA’s ~1.3 million active customers and nearly 2.3 million consultations in 2024 onto Hims & Hers’ platform and is expected to be accretive by 2026.

Vālenz Acquires Kozani Health

April 5, 2021

Healthcare Services

Vālenz, a Great Point Partners-backed healthcare platform, has acquired Kozani Health and integrated its bill review and claim management services as Valenz ProteKHt. The add-on expands Vālenz's payment integrity and claim management capabilities for self-funded and self-insured employers.

Florence Healthcare Acquires VersaTrial

September 25, 2023

Cloud & SaaS

Florence Healthcare, a Site Enablement Platform provider, acquired VersaTrial, a clinical trial site solutions provider, to enhance site enablement capabilities and streamline operations for research sites, sponsors and CROs. The deal will integrate VersaTrial’s features to reduce technology burden, speed feasibility responses, and improve communication across study personnel within Florence’s global network of connected sites.

Verana Health Acquires COTA Healthcare

January 9, 2026

Data & Analytics

Verana Health has acquired oncology-focused COTA (COTA Healthcare) in a transaction supported by a $52 million equity commitment from existing backers. The merger expands Verana's real-world data and analytics capabilities into oncology and gives the combined firm access to more than 95 million patients and over 20,000 contributing clinicians, broadening its offering to biopharma customers across clinical trials and outcomes research.

Voyager Acquisition Corp and VERAXA Biotech Announce Form F-4 Filing for Proposed Business Combination

July 17, 2025

Healthcare Services

VERAXA Biotech AG and Voyager Acquisition Corp. (a SPAC) have filed a Form F-4 registration statement with the SEC in connection with their proposed business combination announced in April 2025. Under the terms, VERAXA shareholders are expected to roll over 100% of their equity and receive approximately 130 million ordinary shares of the combined company, with the deal expected to close in Q4 2025.